» Articles » PMID: 35910801

Raman Spectroscopy Reveals Phenotype Switches in Breast Cancer Metastasis

Abstract

The accurate analytical characterization of metastatic phenotype at primary tumor diagnosis and its evolution with time are critical for controlling metastatic progression of cancer. Here, we report a label-free optical strategy using Raman spectroscopy and machine learning to identify distinct metastatic phenotypes observed in tumors formed by isogenic murine breast cancer cell lines of progressively increasing metastatic propensities. We employed the 4T1 isogenic panel of murine breast cancer cells to grow tumors of varying metastatic potential and acquired label-free spectra using a fiber probe-based portable Raman spectroscopy system. We used MCR-ALS and random forests classifiers to identify putative spectral markers and predict metastatic phenotype of tumors based on their optical spectra. We also used tumors derived from 4T1 cells silenced for the expression of TWIST, FOXC2 and CXCR3 genes to assess their metastatic phenotype based on their Raman spectra. The MCR-ALS spectral decomposition showed consistent differences in the contribution of components that resembled collagen and lipids between the non-metastatic 67NR tumors and the metastatic tumors formed by FARN, 4T07, and 4T1 cells. Our Raman spectra-based random forest analysis provided evidence that machine learning models built on spectral data can allow the accurate identification of metastatic phenotype of independent test tumors. By silencing genes critical for metastasis in highly metastatic cell lines, we showed that the random forest classifiers provided predictions consistent with the observed phenotypic switch of the resultant tumors towards lower metastatic potential. Furthermore, the spectral assessment of lipid and collagen content of these tumors was consistent with the observed phenotypic switch. Overall, our findings indicate that Raman spectroscopy may offer a novel strategy to evaluate metastatic risk during primary tumor biopsies in clinical patients.

Citing Articles

Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy.

Chadokiya J, Chang K, Sharma S, Hu J, Lill J, Dionne J Front Immunol. 2025; 15():1520860.

PMID: 39850874 PMC: 11753970. DOI: 10.3389/fimmu.2024.1520860.


In Depth Mapping of Mesoporous Silica Nanoparticles in Malignant Glioma Cells Using Scattering-Type Scanning Near-Field Optical Microscopy.

Greaves G, Pinna A, Taylor J, Porter A, Phillips C Chem Biomed Imaging. 2024; 2(12):842-849.

PMID: 39735833 PMC: 11672216. DOI: 10.1021/cbmi.4c00053.


Design and Validation of a Multimodal Diffuse Reflectance and Spatially Offset Raman Spectroscopy System for In Vivo Applications.

Mordi A, Karunakaran V, Marium Mim U, Marple E, Rajaram N J Biophotonics. 2024; 18(3):e202400333.

PMID: 39721981 PMC: 11884968. DOI: 10.1002/jbio.202400333.


Real-time monitoring of single dendritic cell maturation using deep learning-assisted surface-enhanced Raman spectroscopy.

Zhang C, Wang M, Wu H, Gao H, Wu P, Guo L Theranostics. 2024; 14(17):6818-6830.

PMID: 39479453 PMC: 11519801. DOI: 10.7150/thno.100298.


Investigating In Vivo Tumor Biomolecular Changes Following Radiation Therapy Using Raman Spectroscopy.

Karunakaran V, Dadgar S, Paidi S, Mordi A, Lowe W, Marium Mim U ACS Omega. 2024; 9(42):43025-43033.

PMID: 39464461 PMC: 11500151. DOI: 10.1021/acsomega.4c06096.


References
1.
Wang X, Qian X, Beitler J, Chen Z, Khuri F, Lewis M . Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res. 2011; 71(5):1526-32. PMC: 3079317. DOI: 10.1158/0008-5472.CAN-10-3069. View

2.
Zheng C, Shao W, Paidi S, Han B, Fu T, Wu D . Pursuing shell-isolated nanoparticle-enhanced Raman spectroscopy (SHINERS) for concomitant detection of breast lesions and microcalcifications. Nanoscale. 2015; 7(40):16960-8. DOI: 10.1039/c5nr05319f. View

3.
Haka A, Shafer-Peltier K, Fitzmaurice M, Crowe J, Dasari R, Feld M . Diagnosing breast cancer by using Raman spectroscopy. Proc Natl Acad Sci U S A. 2005; 102(35):12371-6. PMC: 1194905. DOI: 10.1073/pnas.0501390102. View

4.
Hollier B, Tinnirello A, Werden S, Evans K, Taube J, Sarkar T . FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013; 73(6):1981-92. PMC: 3602160. DOI: 10.1158/0008-5472.CAN-12-2962. View

5.
Winnard Jr P, Zhang C, Vesuna F, Kang J, Garry J, Dasari R . Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes. Oncotarget. 2017; 8(12):20266-20287. PMC: 5386761. DOI: 10.18632/oncotarget.14865. View